This is a contrast between Entera Bio Ltd. (NASDAQ:ENTX) and Nightstar Therapeutics plc (NASDAQ:NITE) based on their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Entera Bio Ltd.||N/A||89.39||10.30M||-1.01||0.00|
|Nightstar Therapeutics plc||N/A||0.00||38.90M||-1.28||0.00|
Demonstrates Entera Bio Ltd. and Nightstar Therapeutics plc earnings per share (EPS), gross revenue and valuation.
Table 2 provides the net margins, return on assets and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Entera Bio Ltd.||0.00%||0%||0%|
|Nightstar Therapeutics plc||0.00%||0%||0%|
Entera Bio Ltd.’s Current Ratio and Quick Ratio are 7 and 7 respectively. The Current Ratio and Quick Ratio of its competitor Nightstar Therapeutics plc are 8.5 and 8.5 respectively. Nightstar Therapeutics plc therefore has a better chance of paying off short and long-term obligations compared to Entera Bio Ltd.
The following table delivered below contains the ratings and recommendations for Entera Bio Ltd. and Nightstar Therapeutics plc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Entera Bio Ltd.||0||0||0||0.00|
|Nightstar Therapeutics plc||0||6||0||2.00|
Nightstar Therapeutics plc on the other hand boasts of a $25.58 average target price and a 0.67% potential upside.
Institutional & Insider Ownership
The shares of both Entera Bio Ltd. and Nightstar Therapeutics plc are owned by institutional investors at 14.7% and 33.3% respectively. 46.55% are Entera Bio Ltd.’s share owned by insiders. Comparatively, insiders own roughly 2.9% of Nightstar Therapeutics plc’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Entera Bio Ltd.||-0.47%||-4.02%||-3.56%||-28.27%||0%||32.16%|
|Nightstar Therapeutics plc||0.12%||0%||81.35%||104.49%||93.76%||121.18%|
For the past year Entera Bio Ltd. was less bullish than Nightstar Therapeutics plc.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel.
Nightstar Therapeutics Limited, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. The companyÂ’s lead product candidate includes NSR-REP1 that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy. The company has a collaboration agreement with University of Oxford for the assistance in conducting clinical trials with its retinal gene therapy candidates; and Preceyes B.V. for the development of a high-precision drug delivery technology in the eye. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.